{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:17:13Z","timestamp":1789906633537,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371411"],"award-info":[{"award-number":["82371411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cellimm.2025.104956","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T22:03:17Z","timestamp":1745964197000},"page":"104956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The real-world impact of corticosteroid-associated adverse events in myasthenia gravis: A patient-reported survey analysis"],"prefix":"10.1016","volume":"411-412","author":[{"given":"Jinyi","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalam","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peicai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengcui","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.cellimm.2025.104956_bb0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis [J]","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cellimm.2025.104956_bb0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders [J]","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cellimm.2025.104956_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1404191","article-title":"Targeting autoimmune mechanisms by precision medicine in myasthenia gravis [J]","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2025.104956_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia gravis treated with autologous hematopoietic stem cell transplantation [J]","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.cellimm.2025.104956_bb0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ana.27029","article-title":"The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases [J]","volume":"96","author":"Brittain","year":"2024","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.cellimm.2025.104956_bb0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases [J]","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.cellimm.2025.104956_bb0035","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study [J]","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.cellimm.2025.104956_bb0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2018.11.008","article-title":"Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: a case report [J]","volume":"29","author":"Sossa Melo","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"4","key":"10.1016\/j.cellimm.2025.104956_bb0045","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis [J]","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.cellimm.2025.104956_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system [J]","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.cellimm.2025.104956_bb0055","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China [J]","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.cellimm.2025.104956_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-02961-9","article-title":"Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis [J]","volume":"19","author":"Zhao","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cellimm.2025.104956_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of Oral steroid therapy for myasthenia gravis [J]","volume":"11","author":"Imai","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.cellimm.2025.104956_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis [J]","volume":"31","author":"Yin","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"9","key":"10.1016\/j.cellimm.2025.104956_bb0075","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2006.01382.x","article-title":"Safety of long-term combined immunosuppressive treatment in myasthenia gravis \u2013 analysis of adverse effects of 163 patients [J]","volume":"13","author":"Rozsa","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.cellimm.2025.104956_bb0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/WNO.0b013e3182536558","article-title":"Safety of prednisone for ocular myasthenia gravis [J]","volume":"32","author":"Bruce","year":"2012","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.cellimm.2025.104956_bb0085","series-title":"Comorbidity Burden and Steroid Use in Generalized Myasthenia Gravis: a Retrospective Analysis of Medicare Fee-for-Service Claims (P4-11.015) [J]","first-page":"3471","volume":"102","author":"Blackowicz","year":"2024"},{"issue":"4","key":"10.1016\/j.cellimm.2025.104956_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ane.12261","article-title":"Glucocorticoids in myasthenia gravis - if, when, how, and how much? [J]","volume":"130","author":"Hoffmann","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.cellimm.2025.104956_bb0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","article-title":"The epidemiology of glucocorticoid-associated adverse events","volume":"20","author":"McDonough","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"10.1016\/j.cellimm.2025.104956_bb0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use [J]","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Care Res."},{"issue":"2","key":"10.1016\/j.cellimm.2025.104956_bb0105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors [J]","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.cellimm.2025.104956_bb0110","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force [J]","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cellimm.2025.104956_bb0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis [J]","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.cellimm.2025.104956_bb0120","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care [J]","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.cellimm.2025.104956_bb0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and lambert\u2013eaton myasthenic syndrome [J]","volume":"14","author":"Murai","year":"2023","journal-title":"Clin. Experiment. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.cellimm.2025.104956_bb0130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan [J]","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.cellimm.2025.104956_bb0135","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-world experience with efgartigimod in patients with myasthenia gravis [J]","volume":"271","author":"Fuchs","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.cellimm.2025.104956_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241251476","article-title":"Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study [J]","volume":"17","author":"Lin","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.cellimm.2025.104956_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.594152","article-title":"Favorable effects of tacrolimus monotherapy on myasthenia gravis patients [J]","volume":"11","author":"Fan","year":"2020","journal-title":"Front. Neurol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874925000413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874925000413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:59:34Z","timestamp":1747155574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874925000413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"alternative-id":["S0008874925000413"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2025.104956","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world impact of corticosteroid-associated adverse events in myasthenia gravis: A patient-reported survey analysis","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2025.104956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104956"}}